Drug profile · INN
allopurinol
ALLOPURINOL SANDOZ
allopurinol (ALLOPURINOL SANDOZ) is a xanthine dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — allopurinol
- US status
- approved
- Class
- Musculo-skeletal system (M04)
- Route
- ORAL
- Patents
- 6
- Programs
- 8
- Data quality
- 0.89
Quick answer
allopurinol (ALLOPURINOL SANDOZ) is a xanthine dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Xanthine dehydrogenase inhibitor
Primary target: Xanthine dehydrogenase/oxidase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2009026621
COMPOSÉ ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2677623
FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES
granted -
CA 2673418
COMPOSE ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2673419
COMPOSITION PHARMACEUTIQUE
granted -
CA 2653382
COMPOSITION STABILISEE COMPRENANT DES INHIBITEURS DE L'ECA
granted -
CA 2628716
PROCESSUS DE REGULATION DE LA DIMENSION DE PARTICULE
granted
Frequently asked questions
What is allopurinol?
allopurinol (ALLOPURINOL SANDOZ) is a xanthine dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for allopurinol?
ALLOPURINOL SANDOZ is a marketed brand name for allopurinol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of allopurinol?
allopurinol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.